Document is current
Any future updates will be listed below
-
Authors
Bang Madsen, Kathrine https://orcid.org/0000-0002-0103-5534
Robakis, Thalia K. https://orcid.org/0000-0003-2919-2555
Liu, Xiaoqin
Momen, Natalie https://orcid.org/0000-0002-9832-8500
Larsson, Henrik https://orcid.org/0000-0002-6851-3297
Dreier, Julie Werenberg
Kildegaard, Helene https://orcid.org/0000-0003-1930-5851
Groth, Jane Bjerg
Newcorn, Jeffrey H. https://orcid.org/0000-0001-8993-9337
Hove Thomsen, Per
Munk-Olsen, Trine
Bergink, Veerle
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH122869)
Sygeforsikring "danmark" is a large Danish Foundation NIHM National Institute of Mental Health is the National US foundation
Det Frie Forskningsråd (1133-00026B)
- License Information
-
More Information
Article History
Received: 21 October 2022
Revised: 25 January 2023
Accepted: 31 January 2023
First Online: 9 February 2023
Competing interests
: HL reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals, and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. HL is editor-in-chief of JCPP Advances. JHN reports the following disclosures (all unrelated to this work): consultant/advisory board for Adlon Therapeutics, Arbor, Corium, Lumos, Medice, Myriad, NLS, OnDosis, Rhodes, and Supernus; research support from Adlon, Otsuka, Shire, Supernus; honoraria for disease state lectures from Otsuka and Takeda, and served as a consultant for the US National Football League. PHT has received speakers fees from MEDICE and Takeda within the last 3 years. All other authors have nothing to declare.
